These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23564321)

  • 1. Markers of HPV infection and survival in patients with head and neck tumors.
    Koslabova E; Hamsikova E; Salakova M; Klozar J; Foltynova E; Salkova E; Rotnaglova E; Ludvikova V; Tachezy R
    Int J Cancer; 2013 Oct; 133(8):1832-9. PubMed ID: 23564321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
    Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
    J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors.
    Simonidesova S; Hamsikova E; Ludvikova V; Klozar J; Vencalek O; Tachezy R
    J Surg Oncol; 2019 Aug; 120(2):117-124. PubMed ID: 30986340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.
    Smith EM; Pawlita M; Rubenstein LM; Haugen TH; Hamsikova E; Turek LP
    Int J Cancer; 2010 Jul; 127(1):111-7. PubMed ID: 19876924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus seropositivity and risks of head and neck cancer.
    Smith EM; Ritchie JM; Pawlita M; Rubenstein LM; Haugen TH; Turek LP; Hamsikova E
    Int J Cancer; 2007 Feb; 120(4):825-32. PubMed ID: 17131312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.
    Fakhry C; Qualliotine JR; Zhang Z; Agrawal N; Gaykalova DA; Bishop JA; Subramaniam RM; Koch WM; Chung CH; Eisele DW; Califano J; Viscidi RP
    Cancer Prev Res (Phila); 2016 Feb; 9(2):135-41. PubMed ID: 26701665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
    Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?
    Smith EM; Rubenstein LM; Ritchie JM; Lee JH; Haugen TH; Hamsikova E; Turek LP
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2087-96. PubMed ID: 18708401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and serologic markers of HPV 16 infection are associated with local recurrence in patients with oral cavity squamous cell carcinoma.
    Huang CG; Lee LA; Liao CT; Yen TC; Yang SL; Liu YC; Li JC; Gong YN; Kang CJ; Huang SF; Fang KH; Chang KP; Lee LY; Hsueh C; Shih SR; Tsao KC
    Oncotarget; 2017 May; 8(21):34820-34835. PubMed ID: 28422732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
    Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
    Spector ME; Sacco AG; Bellile E; Taylor JMG; Jones T; Sun K; Brown WC; Birkeland AC; Bradford CR; Wolf GT; Prince ME; Moyer JS; Malloy K; Swiecicki P; Eisbruch A; McHugh JB; Chepeha DB; Rozek L; Worden FP
    Clin Cancer Res; 2017 Jun; 23(11):2723-2729. PubMed ID: 27872102
    [No Abstract]   [Full Text] [Related]  

  • 12. CD8
    Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
    Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.
    Holzinger D; Wichmann G; Baboci L; Michel A; Höfler D; Wiesenfarth M; Schroeder L; Boscolo-Rizzo P; Herold-Mende C; Dyckhoff G; Boehm A; Del Mistro A; Bosch FX; Dietz A; Pawlita M; Waterboer T
    Int J Cancer; 2017 Jun; 140(12):2748-2757. PubMed ID: 28316084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas.
    Kreimer AR; Clifford GM; Snijders PJ; Castellsagué X; Meijer CJ; Pawlita M; Viscidi R; Herrero R; Franceschi S;
    Int J Cancer; 2005 Jun; 115(2):329-32. PubMed ID: 15688391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
    Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
    Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographic and risk factors in patients with head and neck tumors.
    Tachezy R; Klozar J; Rubenstein L; Smith E; Saláková M; Smahelová J; Ludvíková V; Rotnáglová E; Kodet R; Hamsíková E
    J Med Virol; 2009 May; 81(5):878-87. PubMed ID: 19319944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection.
    López RV; Levi JE; Eluf-Neto J; Koifman RJ; Koifman S; Curado MP; Michaluart-Junior P; Figueiredo DL; Saggioro FP; de Carvalho MB; Kowalski LP; Abrahão M; de Góis-Filho F; Tajara EH; Waterboer T; Boffetta P; Brennan P; Wünsch-Filho V
    Cancer Causes Control; 2014 Apr; 25(4):461-71. PubMed ID: 24474236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological study in Tunisian cervical cancer patients.
    Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
    Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.